New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
06:55 EDTWORWorthington upgraded to Outperform from Neutral at Macquarie
Macquarie upgraded Worthington to reflect earnings growth driven by richly valued product mix, increased cash flow generation, and its M&A driven growth strategy. Price target raised to $36 from $22.
News For WOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2015
09:05 EDTWOROn The Fly: Pre-market Movers
HIGHER: Arrowhead Research (ARWR), up 35% after disclosing top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection... Conatus Pharmaceuticals (CNAT), up 19% after the company's Phase 2 Portal Hypertension clinical trial of emricasan met its primary endpoints... Keryx Biopharmaceuticals (KERX), up 13% after announcing that the European Commission has approved Fexeric for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease. LOWER: Caterpillar (CAT), down 5% after announcing restructuring plans, lowering revenue guidance, and having stock initiated with a Sell rating and a $28 price target at Axiom... Twitter (TWTR), down 1.5% after Citi cut estimates below consensus and lowered its price target to $30. DOWN AFTER EARNINGS: Worthington (WOR), down 12.5%... Accenture (ACN), down 3%.
September 23, 2015
17:23 EDTWORWorthington says 'optimistic' about momentum heading into Q2
Subscribe for More Information
17:22 EDTWORWorthington reports Q1 adjusted EPS 54c, consensus 51c
Reports Q1 revenue $758.1M, consensus $844.96M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use